Showing 5781-5790 of 5956 results for "".
- IOT Launches New Corporate Brandinghttps://modernod.com/news/iot-launches-new-corporate-branding/2479870/Optical technology company IOT has announced a change in brand identity as part of an overall strategy to better communicate its culture, values, and approach to market. The new website and social media profiles are designed to help the company share optical knowledge as well as information abou
- Allergan Announces New Partnership With the International Diabetes Federationhttps://modernod.com/news/allergan-announces-new-partnership-with-the-international-diabetes-federation/2479873/Allergan has announced a collaborative partnership with the International Diabetes Federation (IDF) with the aim of developing a global approach to screen, diagnose, and manage diabetic macular edema (DME). Diabetic eye health is a key concern for IDF and Allergan. The partnership will bri
- Neurolens Appoints Thomas J. Chirillo as Chief Commercial Officerhttps://modernod.com/news/neurolens-appoints-thomas-j-chirillo-as-chief-commercial-officer/2479876/Neurolens announced the appointment of Thomas J. Chirillo as Chief Commercial Officer. An accomplished senior healthcare executive with deep experience in the eye care space, Mr. Chirillo brings almost 4 decades of sales and marketing experience to neurolens. “We’re thrilled to have someon
- FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Diseasehttps://modernod.com/news/fda-grants-lin-bioscience-rare-pediatric-disease-status-for-lbs-008-to-treat-stargardt-disease/2479877/Lin BioScience announced that the FDA has granted rare pediatric disease (RPD) designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. The Priority Review Voucher Program is intended to encourage development of therapies to prevent and treat rare pedi
- Heidelberg Engineering OCT Angiography Module Now Available in the United Stateshttps://modernod.com/news/heidelberg-engineering-oct-angiography-module-now-available-in-the-united-states/2479879/Heidelberg Engineering announced that it has received FDA clearance for its OCT Angiography Module (OCTA). The additional module is now available for new and existing Spectralis upgradeable diagnostic imaging devices.
- Quantel Medical Launches ABSolu Ultrasound Platformhttps://modernod.com/news/quantel-medical-launches-absolu-ultrasound-platform/2479884/Quantel Medical announced it will launch the ABSolu ultrasound platform at the ESCRS meeting in Vienna. Combining leading-edge technologies, the A/B/S/UBM ultrasound platform provides image quality with an exceptional
- Staar Surgical Announces FDA Approval of the Visian Toric ICL for the Correction of Myopia with Astigmatismhttps://modernod.com/news/staar-surgical-announces-fda-approval-of-the-visian-toric-icl-for-the-correction-of-myopia-with-astigmatism/2479890/Staar Surgical announced that the FDA has granted approval of the PMA supplement for the Visian Toric ICL for the correction of myopia with astigmatism. This approval represents an expansion of the Implantable Collamer Lens (ICL) product line for the correction of refractive error in patie
- SightLife Women Advocates Head to Nepal to Support Blindness Prevention Programhttps://modernod.com/news/sightlife-women-advocates-head-to-nepal-to-support-blindness-prevention-program/2479891/SightLife operates an innovative program in rural Nepal that is successfully preventing more than 125 cases of blindness each month, according to a company news release. In October, a group of women leaders in ophthalmology from around the US will visit Nepal to meet with health workers, p
- FDA to Review Eylea (Aflibercept) Injection for the Treatment of Diabetic Retinopathyhttps://modernod.com/news/fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy/2479893/Regeneron Pharmaceuticals announced that the FDA has accepted for review the supplemental biologics license application of Eylea (aflibercept) injection for the treatment of diabetic retinopathy (DR). The target action date for the FDA decision is May 13, 2019. The supplemental biologics l
- Alcon Adds New Ultraviolet-Absorbing Only IOL Options to its AcrySof Portfoliohttps://modernod.com/news/alcon-adds-new-ultraviolet-absorbing-only-iol-options-to-its-acrysof-portfolio/2479895/Alcon expanded its AcrySof IOL portfolio with the introduction of multifocal and multifocal toric ultraviolet (UV)-absorbing IOLs, as well as the introduction of the AcrySof UV-Absorbing monofocal IOL with the UltraSert Preloaded Delivery System. “At Alcon, input from our surgeons is at th